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Abstract:  
Background & Aims: Certain subsets of colorectal serrated polyps (SP) have malignant potential. We 
performed a systematic review and meta-analysis to investigate the association between modifiable 
lifestyle factors and risk for SPs.  
Methods: We conducted a systematic search of Medline, Embase, and Web of Science, for 
observational or interventional studies that contained the terms risk or risk factor, and serrated or 
hyperplastic, and polyps or adenomas, and colorectal (or synonymous terms), published by March 
2016. Titles and abstracts of identified articles were independently reviewed by at least 2 reviewers. 
Adjusted relative risks (RR) and 95% CIs were combined using random effects meta-analyses to 
assess the risk of SP, when possible.  
Results: We identified 43 studies of SP risk associated with 7 different lifestyle factors: smoking, 
alcohol, body fatness, diet, physical activity, medication and/or hormone replacement therapy. 
When we compared the highest and lowest categories of exposure, factors we found to significantly 
increase risk for SP included tobacco smoking (RR, 2.47; 95% CI, 2.12–2.87), alcohol intake (RR, 1.33; 
95% CI, 1.17–1.52), body mass index (RR, 1.40; 95% CI, 1.22–1.61), and high intake of fat or meat. 
Direct associations for smoking and alcohol, but not body fat, tended to be stronger for sessile 
serrated adenomas/polyps than hyperplastic polyps. In contrast, factors we found to significantly 
decrease risks for SP included use of non-steroidal anti-inflammatory drugs (RR, 0.77; 95% CI, 0.65–
0.92) or aspirin (RR, 0.81; 95% CI, 0.67–0.99), as well as high intake of folate, calcium, or fiber. No 
significant associations were detected between SP risk and physical activity or hormone replacement 
therapy.  
Conclusions: Several lifestyle factors, most notably smoking and alcohol, are associated with SP risk. 
These findings enhance our understanding of mechanisms of SP development and indicate that risk 
of serrated pathway colorectal neoplasms could be reduced with lifestyle changes. 
 
KEY WORDS: nutrition, NSAIDs, epidemiology, colon cancer 
Introduction 
Colorectal cancer (CRC) is a heterogeneous disease thought to result from the accumulation of 
various aberrant mutations in the epithelial cells lining the colorectal mucosa 1. It is the third most 
common cancer in males and second most common cancer in females worldwide 2,3. Estimates 
suggest that up to two thirds of CRC are attributable to major lifestyle and modifiable risk factors 4,5.  
CRC arises from pre-malignant polyps, most commonly adenomatous polyps.  Serrated polyps (SP) of 
the colorectum are a diverse group of lesions, largely distinct from adenomatous polyps, 
characterised morphologically by infolding of crypt epithelium. This infolding is thought to be due to 
a decrease in apoptosis 6 producing a characteristic “saw toothed” appearance 7 histologically.  
Before 2003, the vast majority of SP were classified as hyperplastic polyps (HP) 8, and were regarded 
by most pathologists as possessing little or no malignant potential 9. Recent published evidence, 
however, has indicated that there are three distinct sub-categories of SP, most commonly classified 
as hyperplastic polyps (HP), sessile serrated adenomas/polyps (SSA/P) and traditional serrated 
adenomas (TSA) 10. SSA/P and TSA are now understood to harbour malignant potential 11.  
Historically, distinction of SSA/P from HP based on histopathological features has been fraught with 
uncertainty and confusion due to pathologists’ unawareness of this new entity, inconsistent 
terminology and ambiguity over minimum diagnostic criteria for SSA/P 12.  Serrated 
adenocarcinomas have been noted to share morphological features of SP 13, and at least a subset of 
serrated adenocarcinomas have been demonstrated to arise from progression of dysplastic SSA/P.14. 
Thus we now understand that the serrated pathway is a route through which 10-30% of CRC develop 
14,15. This was supported by a recent systematic review and meta-analysis, by Gao et al, revealing a 
strong positive relationship between proximal SP and synchronous advanced neoplasia 16. 
The role of various modifiable and lifestyle risk factors have been described for colorectal 
pathologies, most notably for colorectal adenomas 17-21. To date, only alcohol has been evaluated 
systematically with regards to SP risk and it was found that moderate and heavy alcohol intake 
significantly increased SP risk, by 19% and 60%, respectively 22.  That review included ten studies, 
however only one had analysed SSA/P separately from HP.  To our knowledge, no other lifestyle 
factors have been analysed systematically to determine the effect on risk of serrated colorectal 
polyps. The relatively low prevalence of SSA/P or TSA compared with conventional adenomas also 
make this a suitable topic for meta-analysis, as single center studies may lack the sample size 
required for sufficient precision of statistical associations between lifestyle factors and risk. 
The aim of this novel systematic review and meta-analysis therefore, is to evaluate modifiable and 
lifestyle factors and the risk of SP of the colorectum overall, and by SSA/P, TSA and HP subtypes, 
where possible.  
Methods  
Search strategy  
A search of all relevant literature using the electronic databases Ovid MEDLINE (US National Library 
of Medicine, Bethesda, Maryland, USA), Embase (Reed Elselvier PLC, Amsterdam, Netherlands) and 
Web of Science (Thompson Reuters, Times Square, New York, USA) was conducted. The search 
encompassed all studies published from database inception to March week 1, 2016. The search 
strategy identified studies which contained at least one key word or Medical Subject Heading 
(MeSH) term from the following: risk OR risk factor(s) AND (serrated OR hyperplastic) AND (polyp(s) 
OR adenoma(s)) AND (colorectal OR colorectum OR colon* OR rectal OR rectum).  The search terms 
did not include “metaplastic polyps” as a key word, due to this being outdated terminology.   
 
Study selection 
Titles and abstracts of identified articles were independently reviewed by at least two reviewers (LB 
and ML or HC). The following inclusion characteristics based on ‘PICO(S)’ criteria were agreed for 
screening papers: 
(i) Population: adults aged 18 years and over, undergoing endoscopic investigation of the 
colorectum. 
(ii) Intervention: Assessment of a modifiable risk factor, for example alcohol, smoking, diet, body 
fatness, physical activity, medications or infections. 
(iii) Comparator: Exposure compared with non-exposure (or lower exposure) to a modifiable risk 
factor. 
(iv) Outcome: Risk of serrated colorectal polyps, encompassing hyperplastic polyps (HP), sessile 
serrated adenomas/polyps (SSA/P) and/or traditional serrated adenomas (TSA), presented as 
relative risks (RR) with 95% confidence intervals (CI), or equivalent. 
(v) Study design: Randomised Controlled Trials (RCTs), cohort, case-control or cross-sectional 
studies. 
 All titles and abstracts were reviewed to remove any which were apparently irrelevant to our review. 
Abstracts were eligible for inclusion if the above ‘PICOS’ criteria were fulfilled. The following 
exclusion criteria were also applied when reviewing studies:  exclusive study populations of other co-
morbidities, for example Crohn’s Disease, ulcerative colitis, Barrett’s oesophagus, acromegaly; 
studies of serrated or any other polyposis syndromes; studies of recurrent SP risk, future cancer risk 
and surveillance in polyp patients; studies  with <30 individuals diagnosed with SP in total; studies of 
non-modifiable risk factors for SP, studies of diagnostic and endoscopic techniques for polyp 
detection; reviews. Full text articles and abstracts were reviewed to identify all relevant studies for 
inclusion. Bibliographies of included studies were also reviewed. Where multiple publications 
presented the same risk factor from a study sample, the most recent article was retained. Any 
discrepancies throughout were discussed and resolved by agreement.  
 
Data extraction  
Data extraction of included articles was carried out using piloted data extraction sheets. Detail 
information was recorded from all included studies individually regarding study design and location, 
population characteristics, exclusion criteria, exposure measurement, confounding factors and 
results. This information was reviewed by two reviewers independently (LB and HC), and is 
summarised in Supplementary Tables 1(a-f).  A quality score was derived from applying the 
Newcastle Ottawa Scale 23 to case-control and cohort studies, as shown in Supplementary Table 2. 
 
Statistical Analysis 
Meta-analyses were carried out for SP risk and smoking, alcohol, body fatness, medications, physical 
activity, and dietary factors (including vitamin D, calcium, folate, fiber, fat and meat intakes).  SP risk 
and medication use was conducted according to non-steroidal anti-inflammatory drugs (NSAIDs), 
aspirin and hormone replacement therapy (HRT) use individually.   Risk estimates for each risk factor 
were calculated and weighted to produce an overall pooled estimate with 95% Confidence Intervals 
(CI). These were produced using a random effects model to allow for the expected heterogeneity 
between studies. Two studies presented results by subgroups of HP type24 or SP location25 in the 
original papers – these were pooled prior to inclusion in the overall meta-analysis to avoid 
duplication of their respective controls.  This step was not necessary where sex-specific results were 
presented.  Direct results from RCT interventions were not combined with observational study 
results in meta-analyses, however results from nested case-control studies within RCTs were 
included. All statistical analyses were performed using Intercooled STATA version 11.2 (StataCorp 
2005, College Station, Texas, USA).  Heterogeneity within meta-analyses was quantified using I2 tests. 
An I2 value below 25% suggests there is low heterogeneity between the studies analysed, 50% 
signifies moderate heterogeneity and high heterogeneity is signified by an I2 of 75% or over 26. 
Egger’s regression asymmetry test was applied to quantify the P-value for publication bias 27. 
 
Sub-group and sensitivity analysis 
Stratified analyses were carried out for studies which specified SSA/P or HP as the case group (no 
studies evaluated TSA only). Sensitivity analyses were carried out by systematically removing each 
study in turn in order to decipher its effect on the overall pooled result estimates (Supplementary 
Table 3 (a-f)). Additional post-hoc sensitivity/subgroup analyses were conducted by case-control or 
cross-sectional study design, excluding studies with adenoma patients in their comparator group, 
and combining studies comparing current versus never smoking only (Supplementary Table 3 (a-f). 
Results 
An overview of the study selection process is shown in Figure 1. A search of three databases yielded 
a potential n = 2,446 studies for inclusion, from which n = 43 papers remained for systematic review. 
Some papers reported on multiple risk factors, which included; smoking (n = 29), alcohol 
consumption (n = 14), body fatness (n = 20), physical activity (n = 8), patient medications (n = 12), 
and dietary factors (n = 15), with regards to risk of SP. Details of the included studies and their 
adjustments for relevant confounders are outlined in Supplementary Tables 1(a-f). 
 
Smoking  
The association between smoking and SP risk was assessed by 29 articles which reported 
information from 29 studies, of which 26 articles investigated HP/SP risk24,25,28-50 and six investigated 
SSA/P risk 29-31,51-53. Most studies originated from the USA, five from Europe, and five in Asian 
populations (Supplementary Table 1(a)). 
 
In meta-analysis comparing the highest versus lowest exposure of smoking, a 2.5-fold increased SP 
risk was observed, (RR, 2.47; 95% CI, 2.12-2.87), as shown in Figure 2. The increased risk was evident 
for SP overall, but was stronger for SSA/P risk (RR, 3.40; 95% CI, 1.90-6.07), compared with HP risk 
(RR, 2.34; 95% CI, 2.00-2.73). High heterogeneity was present in all analyses, but there was no 
evidence of publication bias (P = 0.82).  Sensitivity analysis excluding individual studies or subgroup 
analysis did not markedly alter associations (Supplementary Table 3(a)). 
 
Alcohol 
Alcohol intake and risk of SP was assessed by 14 articles reporting on 15 studies, of which three 
studies assessed SSA/P risk29,30,53 and 13 articles reporting on 14 studies investigated HP/SP 
risk.25,29,30,32,38-40,42-44,46,49,54 The majority of studies were conducted in USA populations, two from Asia 
and one from Germany (Supplementary Table 1(b)).  
 Figure 3 summarises the pooled results for studies comparing high versus low alcohol consumption 
and risk of SP, revealing a significant increased risk, RR, 1.33 (95% CI, 1.17-1.52) with moderate 
heterogeneity (I2 = 38%). There was significant evidence of publication bias (P = <0.001). Risk of 
SSA/P when comparing high versus low alcohol intake yielded a RR of 1.85 (95% CI, 1.03-3.32), which 
was slightly attenuated when HP/SP risk was analysed (RR, 1.30; 95% CI, 1.15-1.48).   Sensitivity 
analysis shows the higher result for SSA/P is not driven by the Burnett-Hartman et al study29 
(Supplementary Table 3(b)).  
 
In addition, Omata et al. further investigated risk within classifications of alcoholic beverages. They 
reported non-significant adjusted odds ratios (OR) of 1.53, 1.19 and 0.85 for whisky, beer and sake 
drinkers, respectively 46.  
 
Body fatness 
Body fatness as represented by body mass index (BMI) and risk of SP was assessed by 20 studies, of 
which four investigated SSA/P risk 29,51,53,55 and 16 studies investigated HP/SP risk 25,29,32,35,39,42,44-
48,50,54-57.  Additionally, some studies analysed SP risk according to waist size 58, waist-hip 
ratio/abdominal obesity 39,44,55, peri-colonic or visceral fat volume fraction 59. The majority of studies 
were conducted in the USA, one in Poland, one in China and three in Taiwan (Supplementary Table 
1(c)). 
 
Meta-analyses were possible for studies investigating BMI and SP risk (Figure 4). A significant 
increased SP risk was observed in individuals with the highest versus lowest BMI category, RR, 1.42 
(95% CI, 1.24-1.63). There was moderate heterogeneity, I2 = 55%, and presence of publication bias (P 
= 0.002) in analysis of BMI and SP risk.  The magnitude of association was similar for HP and SSA/P 
subtypes, although statistical significance was lost for the latter (Figure 4).  Sensitivity analysis 
showed similar results to main analysis, with reduced heterogeneity in case-control study meta-
analyses (Supplementary Table 3(c)). One further study reported SP risk per 1 unit increase in BMI, 
and therefore wasn’t included in high versus low BMI meta-analysis, but also reported a 2% 
increased SP risk per 1 unit increment 50.   
 
When investigating SP risk and aspects of visceral adiposity, two studies found non-significant 
increased risks when assessing waist size 58 or waist-hip ratio 39,44, while others identified almost 
two-fold increased risks of HP in individuals with the highest waist-hip ratio 55, peri-colonic or 
visceral adipose volumes 59.   
 
Physical activity 
Eight studies investigated the risk of SP with regards to level of physical activity 29,40,42,44,49,54,55,60, of 
which two also investigated SSA/P risk 29,55.  All studies were conducted within the USA 
(Supplementary Table 1(d)). Figure 5 illustrates a non-significant decreased risk of SP with increased 
levels of physical activity, RR, 0.90 (95% CI, 0.78-1.03). This was consistent for SSA/P and HP 
subtypes (Figure 5) and in all except one sensitivity analysis (Supplementary Table 3(d)).  No 
heterogeneity was observed between studies, nor was there evidence of publication bias (P = 0.62). 
 
Medications 
Twelve articles summarising results from one RCT25 and 11 observational 
studies29,30,40,42,44,45,47,50,54,61,62 investigated the risk of SP for individuals taking NSAIDs and/or aspirin, 
two of which also reported SSA/P risk 29,30, as outlined in Supplementary Table 1(e).  The RCT (which 
was not included in meta-analyses due to the different study design) demonstrated a significant 
protective association for right-sided, but not left-sided, SP when taking 81mg or 325mg of aspirin 
compared with placebo 25.  As shown in Figure 6, significant protective effects were observed for SP 
development in observational studies, when combining overall use of NSAIDs (RR, 0.77; 95%CI, 0.65-
0.92) and aspirin, RR, 0.81 (95% CI, 0.67-0.99). The decreased risk was even stronger for NSAID use 
and SSA/P risk (Figure 6). Results were consistent across sensitivity analyses (Supplementary Table 
3(e)). There was low heterogeneity and little evidence of publication bias for NSAID (P = 0.43) or 
aspirin analyses (P = 0.47).  One study also reported a null association between SP risk and statin use 
50.  
 
Four studies reported on HRT use and SP risk 29,30,44,45, with two reporting on SSA/P risk separately 
from HP risk 29,30.  No significant associations were detected between HRT use and SP risk (RR, 0.99; 
95% CI, 0.78-1.26; I2=0%) or SSA/P risk (Figure 6). No publication bias was evident (P = 0.73).   
 
Dietary factors 
Fifteen articles published on a range of dietary factors and SP risk 25,28,32,38,40,42,44,54,55,63-68, only one of 
which reported SSA/P risk separately 55, as shown in Supplementary Table 1(f). One publication 
summarising RCTs of various supplements identified non-significant reductions in SP risk for those 
assigned to antioxidants or calcium, but not folate 25. Reports from a US cohort also reported no 
significant associations between SP risk and antioxidant vitamin intake from foods 38.   
 
In meta-analyses of observational studies, significant increased risks were observed for individuals 
consuming the highest compared with the lowest intakes of fat (RR, 1.25; 95% CI, 1.10-1.41), and red 
meat (RR, 1.23; 95% CI, 1.07-1.41), with associated low heterogeneity (Figure 7).  The latter finding is 
in line with reports that processed meat also increases SP risk 32. Reduced SP risks were detected for 
individuals consuming the highest compared with the lowest intakes of calcium, fiber and folate, 
although only the latter was significant (RR, 0.65; 95% CI, 0.49-0.85) and all estimates had moderate 
heterogeneity.  Vitamin D intake was not associated with SP risk (Figure 7), which is in agreement 
with another study measuring circulating 25-hydroxyvitamin D status 63.  
 
Other studies investigated SP risk and intake of total energy 25,38,55, carbohydrate 25,38, protein 38, 
magnesium 64, or fish 68 and largely reported non-significant associations, while one study 
demonstrated an increased risk of SP for men consuming high intakes of the polyunsaturated fatty 




This large systematic review and meta-analyses is the first, to our knowledge, to collectively 
investigate modifiable lifestyle factors and their influence on risk of serrated colorectal polyps. 
Meta-analyses revealed statistically significant increased risk of SP associated with smoking, alcohol 
consumption, body fatness, dietary fat and meat, with a statistically significant inverse relationship 
with NSAIDs and aspirin and dietary folate.  The majority of studies related to HP risk; where 
reported, associations for SSA/P tended to be stronger than HP with the exception of body fatness.  
No studies reported on TSA risk.  No associations were detected for physical activity or HRT use, and 
SP risk, while evidence was too sparse for other dietary factors to make any judgements. 
 
There was a 2.5-fold increased risk of SP in smokers, and when risk of SSA/P was analysed, this 
increased to 3.4-fold increased risk. Potential mechanisms for this elevated risk may be explained on 
a molecular level. SP are significantly more likely to contain a BRAF mutation in comparison to non-
SP 69. Limsui et al, carried out a population-based cohort study to investigate smoking and CRC risk 
overall, and by mutation status. They revealed strong correlations between cigarette smoking and 
MSI-high, CIMP-positive and BRAF mutations 70. These MSI-positive, CIMP-positive and/or BRAF-
mutant tumours are thought to arise from SP, specifically SSA/P 44. Smoking may increase the risk of 
DNA mutations within cells of the colorectal mucosa, such that malignant transformation may occur 
via the serrated pathway. Since tobacco smoking is also a potent risk factor for respiratory and upper 
gastrointestinal malignancies 71,72, it would be advisable that smokers abstain where possible, in 
order to reduce their risk of developing neoplasia including CRC. 
 
Pooled analyses for alcohol intake revealed a statistically significant 33% increased risk of SP for 
highest versus lowest intakes. This increased to 85% for SSA/P risk specifically. Alcohol is a known 
risk factor for a number of cancers 73,74. When alcohol is consumed it undergoes metabolism to 
acetaldehyde via alcohol dehydrogenase and cytochrome P450 2E1 (CYP2E1) 75,76. These enzymes 
are associated with a variety of cancers, however in normal physiology they play a role in the general 
detoxification of alcohol 75. Reduced alcohol intake is recommended to reduce SP and CRC risk. 
 
A 42% increased risk was observed when high versus low BMI and risk of SP was assessed, with other 
measures of body fatness also linked to increased risk. A wide range of inflammatory cytokines are 
produced from adipose tissue, some of which are thought to be pro-carcinogenic 77. Individuals with 
high BMIs also have high levels of C-reactive protein 78, and a 2008 systematic review found a direct 
association between C-reactive protein and CRC risk 79. This plausibly suggests that increasing BMI 
puts individuals at increased risk of developing CRC, via increased inflammation. As serrated 
adenocarcinoma accounts for 10-30% of all CRC it is difficult to distinguish if this increased risk is 
mediated through one or more colorectal pathways. Within the current systematic review, some 
studies used alternative measurement methods for body fatness and so further research is required 
using these alternative methods, particularly given suggestions that central adiposity may be of 
greatest importance for colorectal carcinogenesis 43,80.  
 
Analyses for physical activity yielded a non-significant inverse risk of developing SP for highest versus 
lowest levels of activity. Difficulties in measuring an individual’s level of physical activity may be a 
possible explanation. Studies using MET-hours per week showed greater strength of association 42,44, 
in comparison to those evaluating categorical variables such as ever v. never physical activity 49,81. 
The lack of a significant association is surprising, given that several potential mechanisms regarding 
the protective role of physical activity for CRC risk have been postulated. These include enhanced 
immune function, lower bile acid secretions and a reduced stool transit time with increasing physical 
activity 82. Perhaps the protective effect may act largely via the traditional adenoma-carcinoma 
pathway of CRC development, or influence the latter stages of tumorigenesis 83,84.     
 
Use of NSAIDs and/or aspirin was associated with a significant 19-23% decreased risk of SP, 
corroborating results from an RCT of aspirin 25. One included study, Noreen et al. found that women 
with SP carried a 48% increased rate of O6-methylguanine DNA methyltransferase promoter 
methylation compared with women without polyps 45. They reported a 50% suppression in DNA 
methylation with long-term aspirin use and concluded that regular use affects genes controlling 
critical pathways in cancer by stabilising DNA methylation at the promoters of these genes 45, 
resulting in a decreased CRC risk. Furthermore, as outlined earlier, CRC may be associated with an 
increase in inflammatory cytokines 79. This provides a biological basis for the reduced risk of 
neoplasia with NSAID use evident in our meta-analyses. Contrary to noted protective effects of HRT 
for colon cancer risk 85, no associations with SP risk were observed in our meta-analysis.   
 
Five dietary factors were determined to be significantly, or close to significantly, associated with SP 
risk.  Dietary fat and meat intakes were linked with increased risks of SP, which correlates with 
evidence for adenomas and CRC 21,86. Observed protective associations were also detected for 
dietary folate, and to a lesser extent, calcium and fiber, which again corroborates evidence for 
adenomas and CRC 21,86.  Only one dietary study reported SSA/P risk separately from HP risk, and few 
conclusions can be drawn from the other dietary factors investigated, but the overall findings do 
suggest that SP risk can be modified through dietary changes. 
 
Although not an aim of the current review, further research needs to be conducted into the 
molecular epidemiology of SP, to determine the interaction between these lifestyle factors and 
known driver mutations involved in the serrated pathway.  Several studies have investigated SP risk 
in relation to genetic variants linked to the metabolism of the risk factors outlined such as alcohol 87, 
smoking 88,body fatness 81 and diet 28,54,64.  However, only one study has investigated known CRC 
mutations – APC, KRAS and MSI interactions with lifestyle factors (namely, smoking status) and SP 
risk, and found that such mutations were only present in HP patients who smoked, and were not 
seen in non-smokers 41. Expansion of knowledge of such interactions would further aid prevention 
strategies for SP and serrated pathway CRC. 
 
Our systematic review has many strengths, including its large size, and comprehensive inclusion of 
different modifiable lifestyle risk factors have been investigated systematically. Novel meta-analyses 
were carried out, with several yielding statistically significant results. All papers were reviewed by at 
least two independent reviewers and the use of three large databases ensured a large international 
collection of papers undergoing review. No language restrictions were applied in order to reduce any 
potential selection bias. 
 
This systematic review has some limitations, especially regarding classifications used for SP. As 
histological sub-typing of SP is relatively new in the area of diagnostics, many earlier papers are likely 
to have SSA/P classified as HP. Accurate classification is dependent on awareness by the reporting 
pathologist and on robust diagnostic criteria in practice at the time of reporting. It is therefore 
impossible within this review to accurately assess if publications using ‘hyperplastic polyps’ as a 
case/control group solely include HP. As summarised in Supplementary Table 4, year of publication 
or recruitment period, pathologist review, or quality of colonoscopy reported did not clearly 
distinguish between SP sub-types in the majority of publications in the HP/unspecified SP analyses. 
However, the proportion of SSA/P cases within these overall groupings is likely to be small, as HP 
have much higher overall prevalence, and we still observe evidence that magnitudes and directions 
of associations differ between SSA/P only meta-analyses, and the HP/unspecified SP meta-analyses, 
at least for smoking and alcohol. Furthermore, we are confident that our SSA/P only meta-analyses 
do not include HP cases. A second potential limitation is the assessment methods used by the 
research groups. Some used only sigmoidoscopy to investigate the colon. SSA/P are typically located 
in the proximal colon and so these proximal polyps may be missed if only sigmoidoscopy, rather than 
full colonoscopy, has been performed. Again this is a potential area where detection bias could have 
been introduced within individual studies, and SSA/P risk may be underestimated. Some meta-
analyses also showed indications of publication bias (for alcohol and BMI) and heterogeneity (for 
smoking and BMI), reflecting a need for further studies of lifestyle factors and SP risk. 
 
In conclusion, this large comprehensive systematic review has revealed statistically significant 
increases in risk of SP with smoking, alcohol intake, high body fatness, red meat and fat intakes. 
Direct associations for smoking and alcohol, but not body fatness, tended to be stronger for SSA/P 
than HP. There were significant decreased risks of SP with use of aspirin and NSAIDs, and dietary 
folate. There is a need for further studies to be carried out investigating SP risk in the setting of high 
quality colonoscopy and applying internationally agreed nomenclature and definitions 89. Future 
molecular epidemiology studies are also warranted to investigate the underlying pathways linking 
these lifestyle factors in serrated carcinogenesis. Our results strengthen public health messages 
promoting awareness and change in order to reduce the risk of these precancerous lesions and 
consequently CRC.  
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Figure Legends. 
Figure 2 Legend. HPFUS: Health Professionals Follow-Up study; NHS: Nurses Health study. 
Figure 3 Legend. HPFUS: Health Professionals Follow-Up study; NHS: Nurses Health study. 
Figure 4 Legend. BMI: Body mass index.  
Figure 6 Legend. HRT: Hormone Replacement Therapy; NSAID: Non-steroidal anti-inflammatory 
drug.  One further Randomised Controlled Trial (which was not included in meta-analyses due to the 
different study design) also demonstrated a significant 42% reduced risk for right-sided, but not left-
sided, SP when taking 81mg or 325mg of aspirin compared with placebo (Wallace et al, 2009).  
 
Figure 7 Legend. HPFUS: Health Professionals Follow-Up study; NHS: Nurses Health study. 
All studies reported dietary intakes comparing highest v. lowest tertile, quartile or quintile of intake, 
with the exceptions of Lieberman et al, which is presented per 100-International Unit increment of  
vitamin D intake and per 1g increment of fat and fiber intakes, and Burnett-Hartman et al, which 
compared ≥3 v. 0 servings red meat/week. 
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Figure 2. Forest plot of highest v. lowest category of smoking and serrated polyp risk. 
Study-year Smoking exposure 
comparison  
High/Low 
 Relative risk  






    
Anderson (2011) Ever/Never ≥20 pack-yrs  7.31 (3.92-13.63) 18.7 
Buda (2012)  Current/Never  4.90 (1.50-16.40)  11.8 
Burnett-Hartman (2013) Current/Never  2.91 (1.36-6.21) 16.9 
Crockett (2014) Current/Never  1.07 (0.30-3.78) 11.2 
Davenport (2014) Current/Never  5.50 (3.33-9.08) 20.1 
Randles (2015) Current/Never  1.86 (1.25-2.77) 21.3 




    
Burnett-Hartman (2011) Current/Never  2.36 (1.69-3.30) 4.4 
Burnett-Hartman (2013) Current/Never  3.08 (1.91-4.96) 3.6 
Crockett (2014) Current/Never  2.95 (2.02-4.30) 4.1 
Davenport (2014) Current/Never  4.58 (3.16-6.64) 4.2 
Drew (2016) Current/Not current  2.02 (1.58-2.58) 4.8 
Erhardt (2002) Ever/Never  1.79 (1.04-3.06) 3.3 
Figueiredo (2015) Current/Never  2.01 (1.66-2.44) 5.1 
Hassan (2010) Ever/Never  1.98 (1.41-2.78) 4.3 
Hirai (2013) Ever/Never  1.98 (1.49-2.65) 4.6 
Hoffmeister (2010) Current/Never  1.63 (1.31-2.03) 4.9 
Ji (2006) Current/Never  4.40 (3.70-5.20) 5.1 
Kearney, NHS (1995) ≥15cig-d/Never  2.44 (1.63-3.65) 4.0 
Kearney, HPFUS (1995) ≥15cig-d/Never  2.14 (1.28-3.59) 3.4 
Lai (2013) Current/Not current  1.40 (1.02-1.93) 4.4 
Lieberman (2003) Current/Never  2.71 (1.93- 3.81) 4.3 
Martinez (1997) Current/Never  2.45 (1.20-4.98) 2.5 
Martinez (2011) Ever/Never  5.40 (2.60-11.10) 2.5 
Michal (2012) Current/Never  2.04 (1.21-3.44) 3.4 
Morimoto (2002) Current/Never  4.10 (2.20-7.60) 2.9 
Noreen (2014) ≥20 pack-yrs/Never  2.67 (1.72-4.15) 3.8 
Omata (2009) Current/Never  1.95 (1.21-3.12) 3.6 
Oza (2014) Current/Not current  1.10 (0.66-2.00) 3.2 
Qazi (2013)   Ever/Never ≥20 pack-yrs  2.42 (1.70-3.43) 4.3 
Wallace (2009)  Current/Never  1.57 (0.81-3.06) 2.7 
Wang (2014) Current/Never  1.87 (1.42-2.71) 4.4 
Yoshida (2006) Current/Not current  3.00 (1.30-6.90) 2.1 
Overall**   2.34 (2.00-2.73) 100 
 
All serrated polyps 
    
Overall***   2.47 (2.12-2.87)  
  
                      
 
* Test for heterogeneity: I2 =  77 percent, P = 0.001 
** Test for heterogeneity: I2 = 78 percent, P <0.001 




1 0.5 2 3 5 7 
Figure 3. Forest plot of highest v. lowest category of alcohol intake and serrated polyp risk. 
Study-year Alcohol exposure 
comparison  
High/Low 
 Relative risk  






    
Burnett-Hartman (2013) ≥14 v. <1 drink/week  1.09 (0.54-2.20) 37.2 
Crockett (2014) Quartile 4/Quartile 1  2.27 (0.92-5.58) 27.8 
Randles (2015) 
 
≥ v. <2 (men) or 1 
(women) drink/day 
 2.75 (1.31-5.80) 35.0 




    
Burnett-Hartman (2013) ≥14 v. <1 drink/week  0.96 (0.63-1.46) 6.6 
Crockett (2014) Quartile 4/Quartile 1  1.40 (0.99-1.99) 8.4 
Erhardt (2002) >7 v. ≤ 7 g/d  1.42 (0.97-2.07) 7.6 
Fu (2012) Current/Never regular  1.08 (0.86-1.36) 13.3 
Kearney, NHS (1995) >30 v. 0 g/d  1.79 (1.02-3.15) 4.2 
Kearney, HPFUS (1995) >30 v. 0 g/d  1.69 (1.01-2.80) 4.9 
Lai (2011) Habitual/Non-drinker  1.43 (0.97-2.11) 7.3 
Lieberman (2003) >7 drinks/week v Never  1.43 (0.99-2.06) 8.0 
Martinez (1997) >9.4 v. 0 g/d  2.02 (1.05-3.91) 3.2 
Michal (2012) Regular/Unspecified  1.66 (1.06-2.61) 5.9 
Morimoto (2002) ≥8 v. 0 g/d  1.60 (0.70-3.90) 2.0 
Omata (2009) Drinker/Non-drinker  1.53 (0.95-2.44) 5.6 
Wallace (2009) Drinker/Non-drinker  0.99 (0.84-1.17) 16.8 
Yoshida (2006) 
 
 ≥5 v. <5 drinking 
occasions/week 
 1.20 (0.80-1.90) 6.4 
Overall**   1.30 (1.15-1.48) 100 
 
All serrated polyps 
    
Overall***   1.33 (1.17-1.52)  
   
                      
 
* Test for heterogeneity: I2 = 41 percent, P = 0.18 
** Test for heterogeneity: I2 = 34 percent, P = 0.10 
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Figure 4. Forest plot of highest v. lowest category of body mass index and serrated polyp risk. 
Study-year BMI exposure 
comparison  
High/Low 
 Relative risk  






    
Anderson (2011) ≥30 v. Unspecified  2.57 (1.44-4.62) 21.2 
Burnett-Hartman (2013) ≥30 v. <25  1.13 (0.66-1.94) 22.8 
Crockett (2015) ≥30 v. <25  1.11 (0.50-2.45) 15.0 
Randles (2015) Unspecified  1.06 (1.02-1.11) 41.0 




    
Burnett-Hartman (2013) ≥30 v. <25  1.35 (0.97-1.88) 7.6 
Butterly (2014) ≥35 v. <25  1.45 (1.08-1.95) 8.3 
Crockett (2015) ≥30 v. <25  1.36 (0.99-1.88) 7.8 
Erhardt (2002) >24 v. ≤24  1.39 (0.79-2.46) 4.0 
Fu (2012) ≥30 v. 18-<25  1.36 (1.08-1.70) 10.0 
Hirai (2013) ≥25 v. <25  1.34 (1.10-1.64) 10.7 
Lai (2011) ≥27 v. <27  1.59 (1.10-2.28) 7.0 
Leitzmann (2009) ≥30 v. <25  3.76 (2.35-6.01) 5.2 
Martinez (1997) >29.8 v. <23.4  4.50 (1.84-10.97) 2.0 
Morimoto, males (2002) >29.7 v. <24.2  1.79 (0.90-3.40) 3.2 
Morimoto, females (2002) >29.9 v. <22.7  1.10 (0.60-2.00) 3.7 
Noreen (2014) >30 v. 18.5-25  0.78 (0.44-1.35) 4.1 
Omata (2009) >25 v. <22  1.41 (0.81-2.44) 4.2 
Oza et al (2014) ≥30 v. <25  0.69 (0.25-1.90) 1.6 
Wallace et al (2009) ≥30 v. <25  1.23 (1.05-1.45) 11.5 
Wang et al (2014) ≥25 v. <25  1.32 (1.05- 1.71) 9.5 
Overall**   1.42 (1.24-1.63) 100 
 
All serrated polyps 
    
Overall***   1.40 (1.22-1.61)  
  
                      
 
* Test for heterogeneity: I2 = 66 percent, P = 0.03 
** Test for heterogeneity: I2 = 55 percent, P = 0.04 
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Figure 5. Forest plot of highest v. lowest category of physical activity and serrated polyp risk. 
Study-year Physical activity exposure 
comparison  
High/Low 







    
Burnett-Hartman (2013) ≥6 v. 0 hrs/wk   0.86 (0.39-1.87) 61.9 
Crockett (2015) Quartile 4/Quartile 1  0.71 (0.26-1.91) 38.1 




    
Burnett-Hartman (2013) ≥6 v 0 hrs/wk  0.82 (0.51-1.31) 8.4 
Crockett (2015) Quartile 4/Quartile 1  0.98 (0.67-1.43) 12.8 
Fu (2012) >20 v. <1MET-hr/wk  0.89 (0.68-1.17) 24.5 
Lieberman (2003) >36 v. 24-28 index  0.82 (0.60-1.10) 19.9 
Martinez (1997) ≥2205 v. <600 kcal/wk  0.55 (0.25-1.19) 3.0 
Morimoto, males (2002) >47 v. <12.3 MET-hr/wk  0.70 (0.30-1.20) 3.9 
Morimoto, females (2002) >41.2 v. <11 MET-hr/wk  1.70 (0.90-3.20) 4.6 
Wallace (2005) >335 v. <263 MET-hr/wk  1.04 (0.73-1.49) 14.7 
Yoshida (2006) 
 
 ≥3 v. <3 activity 
occasions/week 
 0.80 (0.50-1.30) 8.2 
Overall**   0.90 (0.78-1.03) 100 
 
All serrated polyps 
    
Overall***   0.90 (0.78-1.03)  
  
                      
 
* Test for heterogeneity: I2 = 0 percent, P = 0.77 
** Test for heterogeneity: I2 = 0 percent , P = 0.48 
*** Test for heterogeneity: I2 = 0 percent , P = 0.58, Crockett et al SSA/P results excluded due to overlap with HP/SP results. 
 
 
    
0.25 0.5 0.75 1 2 3 
Figure 6. Forest plot of highest v. lowest category of medication use and serrated polyp risk. 
Study-year Medication exposure 
comparison  
High/Low 





NSAIDs     
Sessile serrated 
adenomas/polyps 
    
Burnett-Hartman (2013) Current/Never  0.64 (0.41-1.01) 76.4 
Crockett (2014) Regular user/Unspecified  0.56 (0.25-1.26) 23.6 




    
Burnett-Hartman (2013) Current/Never  0.90 (0.69-1.16) 17.1 
Crockett (2015) Regular user/Unspecified  1.04 (0.78-1.38) 16.0 
Drew (2016) User/Non-user  0.10 (0.01-0.77) 0.7 
Fu (2012) Current/Never  0.84 (0.69-1.01) 20.6 
Johnson (2010) >60 v. <4 tablets/month  0.70 (0.60-0.90) 20.1 
Lieberman (2003) ≥Daily v. Never user  0.75 (0.56-0.99) 16.0 
Martinez (1997) Use ≥7 v. <7 times/wk  0.29 (0.12-0.67) 3.7 
Morimoto (2002) Regular/Non-user  0.60 (0.30-1.10) 5.9 
Overall**   0.77 (0.65-0.92) 100 
     
Aspirin     
Hyperplastic/serrated 
polyps 
    
Drew (2016) User/Non-user  0.92 (0.72-1.17) 28.6 
Johnson (2010) >60 v. <4 tablets/month  0.70 (0.50-0.90) 24.1 
Morimoto (2002) Regular/Non-user  1.00 (0.60-1.60) 12.0 
Murff (2011) Regular/Non-user  0.90 (0.65-1.25) 21.2 
Noreen (2014) ≥2 years Use/Non-user  0.36 (0.16-0.74) 5.7 
Oza (2014) User/Non-user  0.83 (0.45-1.50) 8.5 
Overall***   0.81 (0.67-0.99) 100 
     
HRT     
Sessile serrated 
adenomas/polyps 
    
Burnett-Hartman (2013) Postmenopausal Ever/Non User   1.45 (0.78-2.69) 75.2 
Crockett (2014) User/Non-user  1.29 (0.44-3.80) 24.8 




    
Burnett-Hartman (2013) Postmenopausal Ever/Non User   0.92 (0.61-1.38) 30.6 
Crockett (2015) User/Non-user  1.22 (0.79-1.89) 26.5 
Morimoto (2002) Ever/Never User  0.70 (0.40-1.10) 20.3 
Noreen (2014) Ever age >50/Non User   1.19 (0.73-1.92) 22.6 
Overall*****   0.99 (0.78-1.26) 100 
  
                      
 
* Test for heterogeneity: I2 = 0 percent, P = 0.78 
** Test for heterogeneity: I2 = 56 percent, P = 0.03 
*** Test for heterogeneity: I2 = 33 percent, P = 0.19 
**** Test for heterogeneity: I2 = 0 percent, P = 0.85 
***** Test for heterogeneity: I2 = 0 percent, P = 0.34 
 
     1 0.5 0.75 2 
 Figure 7. Forest plot of highest v. lowest category of dietary intakes and serrated polyp risk. 
Study-year  Relative risk  




Vitamin D    
Kearney (1995)  0.99 (0.65-1.51) 2.5 
Lieberman (2003)  1.00 (0.99-1.01) 96.5 
Morimoto (2002)  1.60 (0.80-2.90) 1.1 
Overall*  1.01 (0.94-1.07) 100 
 
Calcium 
   
Fu (2012)  0.73 (0.56-0.96) 33.4 
Lieberman (2003)  1.00 (0.99-1.01) 42.8 
Martinez (1997)  0.32 (0.11-0.96) 7.7 
Morimoto (2002)  0.60 (0.30-1.10) 16.2 
Overall**  0.76 (0.55-1.06) 100 
    
Folate    
Fu (2012)  0.73 (0.55-0.96) 46.5 
Kearney, NHS (1995)  0.45 (0.28-0.74) 23.3 
Kearney, HPFUS (1995)  0.71 (0.49-1.11) 30.2 
Overall***  0.65 (0.49-0.85) 100 
    
Fiber    
Crockett (2015)  0.73 (0.50-1.07) 9.6 
Fu (2012)  0.84 (0.64-1.10) 14.9 
Kearney, NHS (1995)  0.79 (0.48-1.35) 5.9 
Lieberman (2003)  1.00 (0.98-1.01) 38.9 
Martinez (1997)  0.30 (0.10-0.88) 1.5 
Platz (1997)  0.82 (0.50-1.36) 6.1 
Wallace (2009)  0.90 (0.75-1.07) 23.1 
Overall****  0.88 (0.77-1.01) 100 
    
Fat    
Crockett (2015)  1.48 (1.02-2.13) 10.9 
Fu (2012)  1.24 (0.95-1.62) 21.1 
Kearney, NHS (1995)  1.02 (0.62-1.68) 5.9 
Kearney, HPFUS (1995)  0.96 (0.66-1.52) 8.4 
Martinez (1997)  0.90 (0.27-2.95) 1.0 
Morimoto (2002)  1.10 (0.60-2.00) 4.1 
Wallace (2009)  1.31 (1.10-1.57) 48.5 
Overall*****  1.25 (1.10-1.41) 100 
    
Red Meat    
Burnett-Hartman (2011)  1.34 (0.92-1.94) 13.8 
Crockett (2015)  1.18 (0.81-1.71) 13.4 
Fu (2012)  1.36 (1.04-1.78) 25.8 
Wallace (2009)  1.14 (0.93-1.39) 47.0 
Overall******  
 
1.23 (1.07-1.41) 100 
    
 
* Test for heterogeneity: I2 = 4 percent, P = 0.36 
** Test for heterogeneity: I2 = 74 percent, P = 0.009 
*** Test for heterogeneity: I2 = 35 percent, P = 0.21 
**** Test for heterogeneity: I2 = 48 percent, P = 0.07 
***** Test for heterogeneity: I2 = 0 percent, P = 0.72 
****** Test for heterogeneity: I2 = 0 percent, P = 0.72 
 
    1 0.5 0.75 2 3 















































































SESSILE SERRATED ADENOMA/POLYPS                   





90 200 Screening participants 
undergoing colonoscopy 




             





23* 258 Symptomatic and screening 
patient undergoing colonoscopy 
SSA v. No 
polyps 
Not reported              





149 1037 Patients undergoing index 
colonoscopy for any indication 




             












             









             






Symptomatic and screening 
patients undergoing colonoscopy 
SSA v. No 
polyps 
Not reported              
 
HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED 
               





691 772 Patients undergoing colonoscopy 
for any indication 




             





431 1037 Patients undergoing index 
colonoscopy for any indication 




             













             








             
                    














































































HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                  









             





71 224 Patients undergoing colonoscopy HP v. No 
polyps 
Interview              
Figueiredo et al (2015) 
USA 
Nested case-
control study in 
RCT 
633 2667 Patients with history of 
conventional adenomas 
undergoing colonoscopy 
SP v. No SP Questionnaire              




study in RCT 
157 786 Screening  participants 
undergoing CTC and colonoscopy 
HP v.  No 
polyps 
Questionnaire # #  # #         





532 3647 Patients who had complete 
colonoscopy 
HP/SP v. No 
polyps 
Not reported              






654 1846 Screening  participants 
undergoing colonoscopy 




             
Ji et al (2006)  
USA 
Nested case-
control study in 
RCT 
1545 33667 Screening arm of PLCO Trial,  
participants undergoing 
sigmoidoscopy 




    # #     #   











Participants who had undergone 
sigmoidoscopy/colonoscopy 
within follow-up period 




 #            





243 3759 Self-referred patients undergoing 
flexible sigmoidoscopy 
HP v. No 
polyps 
Questionnaire              





391 1441 Asymptomatic patients from 13 
Veteran Affairs medical centres 
undergoing colonoscopy 
HP v. No 
polyps 
Clinical survey              








             
                    
 
Table 1 (a) continued. Characteristics of studies investigating smoking and the development of serrated colorectal adenomas/polyps. 
 
 
Adjusted confounders: Age; Sex; Race; Alcohol; BMI: Body mass index; Phys activity: Physical activity; Diet: any aspect of dietary intake; Diabetes; Study site; Education; Family Hx: Family 















































































HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                 





90 436 Screening  participants (males) 
undergoing colonoscopy. 
HP v. No 
polyps 
Questionnaire  #            




215 963 Participants undergoing 
screening colonoscopy 





Not reported – did state multivariate analysis. 




219 708 Symptomatic and screening 
patient undergoing colonoscopy 





             






106 440 Screening  participants (females) 
undergoing colonoscopy 





 #            





132 586 Patients undergoing full 
colonoscopy 
HP v. No 
polyps 
Questionnaire              





53** 1041 Screening patients undergoing 
colonoscopy 




             







Screening  participants   
undergoing colonoscopy 




Not reported – did state multivariate analysis. 




within RCTs***  
812 2018 Patients with history of colorectal 
adenoma and undergoing 
surveillance colonoscopy 
HP/SSA v.  
No polyps 
Questionnaire   # # # # # #  # # # # 





210 1379 Asymptomatic  participants   
undergoing colonoscopy 
HP v. No HP Interview      # #   # # #  




35 183 Symptomatic patients undergoing 
colonoscopy 
HP v. No 
polyps 
Questionnaire              
Abbreviations: FFQ: Food frequency questionnaire; HP: Hyperplastic polyps; HPFUS: Health Professionals Follow Up Study; NHS: Nurses Health Study; PSP: Proximal serrated polyp; RCT: 
Randomised Controlled Trial; SSA : Sessile Serrated Adenomas. 
* Buda et al did include >30 serrated polyps including hyperplastic polyps and therefore met inclusion criteria, but only reported results for sessile serrated adenomas. 
** Oza et al case numbers estimated from polyp detection rates. 
***Wallace et al included pooled data from three separate placebo-controlled randomised controlled trials of antioxidants, calcium, or aspirin/folate supplements. 
#: Confounder tested for but not included in model or confounder not applicable due to homogenous study population or randomisation. 
















































































SESSILE SERRATED ADENOMA/POLYPS                   





149 1037 Patients undergoing index 
colonoscopy for any indication 




             












             






Symptomatic and screening 
patient undergoing colonoscopy 
SSA v. No 
polyps 
Not reported              
 
HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED 
               





431 1037 Patients undergoing index 
colonoscopy for any indication 
SP v. No 
polyps 
Questionnaire              













             





71 224 Patients undergoing colonoscopy HP v. No 
polyps 
Interview              





662 3,764 Symptomatic and screening 
patients undergoing colonoscopy 




             












Participants who had undergone 
sigmoidoscopy/colonoscopy 
within follow-up period 




s and FFQs  
  #           





243 3759 Self-referred patients undergoing 
flexible sigmoidoscopy. 
HP v. No 
polyps 
Questionnaire    #          




391 1441 Asymptomatic participants   
undergoing colonoscopy 
HP v. No 
polyps 
Questionnaire              




Adjusted confounders: Age; Race; Sex; Smoking; BMI: Body mass index; Phys activity: Physical activity; Diet: any aspect of dietary intake; Diabetes; Study site; Education; Family Hx: Family 
history; NSAID use: Non-steroidal anti-inflammatory drug use; HRT use: Hormone replacement therapy use.  
Abbreviations: CTC: Computed Tomography Colonography; FFQ: Food frequency questionnaire; HP: Hyperplastic polyps; SSA: Sessile Serrated Adenomas. 
#: Confounder tested for but not included in model or confounder not applicable due to homogenous study population. 
*Wallace et al included pooled data from three separate placebo-controlled randomised controlled trials of antioxidants, calcium, or aspirin/folate supplements; Met inclusion criteria since 















































































HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                




81 480 Symptomatic and screening 
patients (males) undergoing  
sigmoidoscopy or colonoscopy 




  #           





215 963 Screening patients undergoing 
colonoscopy 
HP v. No 
polyps 
Interview Not reported    




219 708 Symptomatic and screening 
patients  undergoing colonoscopy  





             





132 586 Symptomatic patients undergoing 
colonoscopy 
HP v. No 
polyps 
Questionnaire              





812 2018 Patients with history of colorectal 
adenoma and undergoing 
surveillance colonoscopy 
HP/SSA v.  
No polyps 
Questionnaire  #   # # # #  # # # # 





35 183 Symptomatic patients undergoing 
colonoscopy 
HP v. No 
polyps 
Questionnaire              


















































































SESSILE SERRATED ADENOMA/POLYPS                   
Anderson et al (2011)  Cross-sectional 
study 
90 200 Symptomatic and screening 
patients undergoing 
colonoscopy 




             





149 1037 Patients undergoing index 
colonoscopy for any indication 





             








1316 Patients undergoing 
colonoscopy 




(BMI; WH ratio) 
             






Symptomatic and screening 
patient undergoing 
colonoscopy 




             
HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                





431 1037 Patients undergoing index 
colonoscopy for any indication 




             





666 4198 Screening participants 
undergoing colonoscopy 




             








1316 Patients undergoing 
colonoscopy 





(BMI; WH ratio) 
             





1076 1646 Patients undergoing 
colonoscopy 





             





71 224 Patients undergoing 
colonoscopy 
HP v. No 
polyps 
Interview              




662 3764 Symptomatic and screening 
patients undergoing 
colonoscopy 




             



















































































HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                





532 3647 Patients  undergoing complete 
colonoscopy 




             




243 3759 Self-referred patients 
undergoing flexible 
sigmoidoscopy. 





             




175 953 Asymptomatic screening 
participants (females) 
undergoing colonoscopy. 






  #           





341 3062 Screening patients undergoing 
colonoscopy  





             




study in RCT 
240 929 Asymptomatic patients 
undergoing colonoscopy 
HP v. No HP CTC  
(PFVF, VFVF) 
             




81 480 Symptomatic and screening 
patients (males) undergoing  
sigmoidoscopy or colonoscopy 





  #           





219 708 Symptomatic and screening 
patients undergoing 
colonoscopy 





(BMI, WH ratio) 
             






106 440 Screening  participants 
(females) undergoing 
colonoscopy 






  #           





132 586 Symptomatic patients 
undergoing colonoscopy 




             





53* 1041 Screening patients undergoing 
colonoscopy 




             
Table 1 (c) continued. Characteristics of studies investigating body fatness and the development of serrated colorectal adenomas/polyps. 
 
 
Adjusted confounders: Age; Race; Sex; Smoking; Phys activity: Physical activity; Diet: any aspect of dietary intake; Diabetes; Study site; Education; Family Hx: Family history; NSAID use: Non-
steroidal anti-inflammatory drug use; HRT use: Hormone replacement therapy use; Alcohol.  
Abbreviations: BMI: Body mass index; CTC: Computed tomographic colonography; FFQ: Food frequency questionnaire; GCHP: goblet cell hyperplastic polyp; HP: Hyperplastic polyps; MVHP: 
microvesicular hyperplastic polyp; PFVF: Pericolonic fat volume fraction; PSP: Proximal Serrated Polyps; RCT: Randomised Controlled Trial; SSA: Sessile Serrated Adenomas; SP: Serrated 
polyps; VFVF: Visceral fat volume fraction; WH ratio: Waist-hip ratio. 
* Oza et al case numbers estimated from polyp detection rates. 
** Randomised controlled trial of calcium supplements – this is adjusted for in analysis; Met inclusion criteria since individuals had a history of adenoma, but not serrated polyps. 

















































































HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                





812 2018 Patients with history of 
colorectal adenoma and 
undergoing surveillance 
colonoscopy 




 #   # # # #  # # # # 




210 1379 Asymptomatic participants 
undergoing colonoscopy 
HP v. No HP Interview  
(BMI) 
    # #   # # #   












































































SESSILE SERRATED ADENOMA/POLYPS                   





149 1037 Patients undergoing index 
colonoscopy for any indication 
SSA v. No 
polyps 
Interviewed 
Questionnaire   
             








1316 Patients undergoing 
colonoscopy 




             
HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                





431 1037 Patients undergoing index 
colonoscopy for any indication 




             








1316 Patients undergoing 
colonoscopy 





             




662 3764 Symptomatic and screening 
patients undergoing 
colonoscopy 
HP v. No 
polyps 
Interview              





391 1441 Asymptomatic participants 
undergoing colonoscopy 
HP v. No 
polyps 
Questionnaire              




81 480 Symptomatic and screening 
patients (males) undergoing  
sigmoidoscopy or colonoscopy 
HP v. No 
polyps 
Interview              




219 708 Symptomatic and screening 
patients  undergoing 
colonoscopy  





             





156 787 Patients with history of 
colorectal adenoma and 
undergoing surveillance 
colonoscopy. 
HP v.  No HP Interviewed 
Questionnaire 
             




35 183 Symptomatic patients 
undergoing colonoscopy 
HP v. No 
polyps 
Questionnaire              
Adjusted confounders: Age; Race; Sex; Smoking; BMI: Body mass index; Diet: any aspect of dietary intake; Diabetes; Study site; Education; Family Hx: Family history; NSAID use: Non-
steroidal anti-inflammatory drug use; HRT use: Hormone replacement therapy use; Alcohol. Abbreviations: HP: Hyperplastic polyps; SSA: Sessile Serrated Adenomas; SP: Serrated polyps; 
RCT: Randomised Controlled Trial. * Randomised controlled trial of calcium supplements – this is adjusted for in analysis; Met inclusion criteria since individuals had a history of adenoma, 
but not serrated polyps. #: Confounder tested for but not included in model or confounder not applicable due to homogenous study population. 














































































SESSILE SERRATED ADENOMA/POLYPS                   





149 1037 Patients undergoing index 
colonoscopy for any indication 





             








1316 Patients undergoing 
colonoscopy 





             
HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                





431 1037 Patients undergoing index 
colonoscopy for any indication 




             








1316 Patients undergoing 
colonoscopy 





(NSAID, HRT)  
             





1076 1646 Patients undergoing 
colonoscopy 






             




662 3764 Symptomatic and screening 
patients undergoing 
colonoscopy 




             







1646 38,396 Screening participants 
undergoing sigmoidoscopy 
Left-sided 







      #       





391 1441 Asymptomatic participants 
undergoing colonoscopy. 




             




81 480 Symptomatic and screening 
patients (males) undergoing  
sigmoidoscopy or colonoscopy 




             




Adjusted confounders: Age; Race; Sex; Smoking; BMI: Body mass index; Phys activity: Physical activity; Diet: any aspect of dietary intake; Diabetes; Study site; Education; Family Hx: Family 
history; HRT use: Hormone replacement therapy use (for NSAID/Aspirin analyses only); Alcohol.  
Abbreviations: BMI: Body mass index;; HP: Hyperplastic polyps; NSAID: Non-steroidal anti-inflammatory drug; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; PSP: 
Proximal Serrated Polyps; RCT: Randomised Controlled Trial; SSA: Sessile Serrated Adenomas; SP: Serrated polyps. 
* Fu et al 2012 and Murff et al 2011 reported results from the same population (Tennessee Colorectal Polyp Study) – Fu et al results were maintained for overall ‘NSAID’ results in 
corresponding meta-analysis, and Murff et al results were used for aspirin-specific analysis.  
** Oza et al case numbers estimated from polyp detection rates. 
***Wallace et al met inclusion criteria since individuals had a history of adenoma, but not serrated polyps. 















































































HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                






219 708 Symptomatic and screening 
patients undergoing 
colonoscopy 




questionnaire      
(NSAID, 
Aspirin, HRT) 
             






499 3431 Symptomatic and screening 
patients undergoing 
colonoscopy.  





             






106 440 Screening  participants 
(females) undergoing 
colonoscopy 






  #           





53** 1041 Screening patients undergoing 
colonoscopy 





             
Wallace et al (2009) 
USA*** 
RCT 812 2018 Patients with history of 
colorectal adenoma and 
undergoing surveillance 
colonoscopy 
HP/SSA v.  
No polyps 
RCT of aspirin 
81mg or 325 mg 
v. placebo 
 #   # # # #  # # # # 



















































































SESSILE SERRATED ADENOMA/POLYPS                   








1316 Patients undergoing 
colonoscopy 
SSA v No 
polyps 
FFQ 
(Fat; Red meat; 
Fibre) 
             
HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                




85 225 Participants of a clinic-based 
study undergoing 
colonoscopy. 
HP v. No 
polyps 
LC MS  
(25-hydroxy-
vitamin D) 
 #            





691 772 Patients undergoing 
colonoscopy for any indication 





             








1316 Patients undergoing 
colonoscopy 




(Fat; Red meat; 
Fibre) 
             




210 1306 Symptomatic and screening 
patients undergoing 
colonoscopy 






           #  




71 224 Symptomatic patients 
undergoing colonoscopy 




(Ham, sausage)  
             




662 3764 Symptomatic and screening 
patients undergoing 
colonoscopy 
HP v. No 
polyps 
Telephone 
survey, FFQ  
(Red meat; Fiber, 
Calcium; Folate) 
             




662 3764 Symptomatic and screening 
patients undergoing 
colonoscopy 






             
                    




















































































HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                





175 15984 Participants who self-reported 
that they had undergone 
sigmoidoscopy or colonoscopy 
during study follow-up period 
Distal HP v. 
No HP 
Two 61-item and 





  #           





219 12922 Participants who self-reported 
that they had undergone 
sigmoidoscopy or colonoscopy 
during study follow-up period 
Distal HP v. 
No HP 




  #           




391 1441 Asymptomatic participants   
undergoing colonoscopy 




Calcium; Vit D; 
multivitamins) 
             
Martinez et al (1997)  
Spain  
Cross-sectional study 81 480 Symptomatic and screening 
patients undergoing  
sigmoidoscopy or colonoscopy 
HP v. No 
polyps 
Interviewed 138-
item FFQ  
(Fiber; Calcium; 
Total fat) 
             




219 708 Symptomatic and screening 
patients  undergoing 
colonoscopy  
HP v. No 
polyps 
FFQ  
(Fat; Vit D; 
Calcium; 
multivitamins) 
             




544 3166 Patients undergoing 
colonoscopy.  





  #           





327 16448 Participants who underwent 
endoscopy during study 
follow-up period. 
HP v. No HP 131-item FFQ 
(Fiber) 
  #           




194 626 Symptomatic and screening 
patients scheduled for 
colonoscopy. 




             
Table 1 (f) continued. Characteristics of studies investigating dietary factors and the development of serrated colorectal adenomas/polyps. 
 
 
Adjusted confounders: Age; Race; Sex; Smoking; BMI: Body mass index; Phys activity: Physical activity; Alcohol consumption; Diabetes; Study site; Education; Family Hx: Family history; NSAID 
use: Non-steroidal anti-inflammatory drug use; HRT use: Hormone replacement therapy use.  
Abbreviations: CTC: Computed tomographic colonography; FFQ: Food frequency questionnaire; HP: Hyperplastic polyps; PUFAs: Poly-unsaturated Fatty Acid; SSA: Sessile Serrated 
Adenomas; SP: Serrated polyps; Vit: Vitamins. 
* Studies all reported results from the same population (Tennessee Colorectal Polyp Study) – where dietary factors overlapped, the most recent publication was used for meta-analysis.  
** Studies all reported results from the same population (Health Professionals Follow Up Study) – where dietary factors overlapped, the most recent publication was used for meta-analysis. 
***Wallace et al met inclusion criteria since individuals had a history of adenoma, but not serrated polyps. 
















































































HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED                
Wallace et al (2009) 
USA*** 
Pooled data from 
RCTs and nested 
case-control studies 
within these 
812 2018 Patients with history of 
colorectal adenoma and 
undergoing surveillance 
colonoscopy 
HP/SSA v.  
No polyps 
RCT of calcium, 
antioxidants, 
folate  v. placebo 




 #   # # # #  # # # # 
















Adams et al (2011) 
Anderson et al (2011) 
Buda et al (2012) 
Burnett-Hartman et al (2011) 
Burnett-Hartman et al (2013) 
Butterly et al (2014) 
Crockett et al (2014) Abstract 
Crockett et al (2015) Abstract 
Dai et al (2007) 
Davenport et al (2014) Abstract 
Drew et al (2016) 
Erhardt et al (2002) 
Figueiredo et al (2015) 
Fu et al (2011) 
Fu et al (2012) 
Hassan et al (2010) 
Hirai et al (2013) Abstract 
Hoffmeister et al (2010) 
Ji et al (2006) 
Johnson et al (2010) 
Kearney et al (1995) 
Lai et al (2011) 
Lieberman et al (2003) 
Lietzmann et al (2009)  
Liu et al (2010) 
Liu et al (2015) 
Martinez et al (1997) 
Martinez et al (2011) 
Michal et al (2012) 
Morimoto et al (2002) 
Murff et al (2011) 
Murff et al (2012) 
Noreen et al (2014) 
Omata et al (2009) 
Oza et al (2014) Abstract 
Platz et al (1997) 
Poole et al (2007) 
Qazi et al (2013) Abstract 
Randles et al (2015) Abstract 
Wallace et al (2005) 
Wallace et al (2009) 
Wang et al (2014) 
Yoshida et al (2006) 
 
* 0 0 * 
* * 0 * 
* * 0 * 
* * 0 * 
* * 0 * 
* * * * 
* 0 * * 
* 0 * * 
* 0 0 * 
* 0 0 * 
* * 0 * 
* 0 0 * 
0 * * * 
* 0 0 * 
* 0 0 * 
* 0 0 * 
* 0 0 * 
* * * * 
* 0 * * 
* 0 * * 
0 * * * 
* * 0 * 
* 0 0 * 
* 0 0 * 
* * 0 * 
* * 0 * 
* * 0 * 
* 0 * * 
* 0 0 * 
* * 0 * 
* 0 0 * 
* 0 0 * 
* 0 * * 
* * 0 * 
0 * 0 * 
0 * * * 
* * 0 * 
* 0 * * 
* 0 0 * 
* 0 * * 
* 0 * * 
* * 0 * 














































* * * 
* * * 
0 * * 
0 * * 
0 * * 
* * * 
* * * 
* * * 
0 * * 
0 * * 
* * * 
* * * 
* * 0 
0 * * 
0 * * 
* * * 
0 * * 
* * * 
* * * 
* * * 
0 * * 
* * * 
* * * 
* * * 
* * * 
* * * 
0 * * 
* * * 
* * * 
* * * 
0 * * 
0 * * 
0 * * 
* * * 
* * * 
0 * * 
* * * 
* * * 
0 * * 
* * * 
* * * 
* * * 














































*Categories for Case-control studies include: Selection (adequate SP case definition, SP case representativeness, control 
selection, non-SP control definition), Comparability (adjustment/study design accounts for important factors – we selected age 
and sex), and Exposure (ascertainment of risk factor, similar method of risk factor ascertainment for cases and controls, and 
response rates). Categories for Cohort studies include: Selection (risk factor-exposed cohort representativeness, cohort 
selection, ascertainment of risk factors, evidence of no SP at the start of the study), Comparability (adjustment/study design 
accounts for important factors – we selected age and sex), and Outcome (SP assessment, adequate follow-up length for SP 
detection, and adequacy of cohort follow-up).   
**It should be noted that scoring is somewhat subjective due to potential non-reporting of each of these factors, particularly for 
abstracts, rather than being reflective of the study design itself.  
Supplementary Table 3 (a). Sensitivity and subgroup meta-analyses of smoking and serrated polyp risk. 
 
 
Study omitted Pooled relative risk  
(95 percent CI) 
Heterogeneity estimate,  
I-squared percent, P-value 
Smoking – Sessile serrated adenoma/polyp only – Excluding individual studies 
Anderson 2.86 (1.58-5.16) 71%, P = 0.008 
Buda 3.22 (1.69-6.14) 81%, P <0.001 
Burnett-Hartman 3.48 (1.73-7.00) 81%, P <0.001 
Crockett 3.92 (2.15-7.15) 78%, P <0.001 
Davenport 3.01 (1.53-5.92) 76%, P = 0.003 
Randles 4.17 (2.45-7.09) 56%, P = 0.06 
OVERALL 3.40 (1.90-6.07) 77%, P = 0.001  
Smoking – Hyperplastic/serrated polyps – Excluding individual studies 
Burnett-Hartman 2011 2.34 (1.99-2.75) 79%, P <0.001 
Burnett-Hartman 2013 2.32 (1.98-2.71) 79%, P <0.001 
Crockett 2.32 (1.98-2.72) 79%, P <0.001 
Davenport 2.27 (1.95-2.65) 77%, P <0.001 
Drew 2.36 (2.00-2.77) 79%, P <0.001 
Erhardt 2.36 (2.02-2.77) 79%, P <0.001 
Figueiredo 2.36 (2.00-2.78) 79%, P <0.001 
Hassan 2.36 (2.01-2.77) 79%, P <0.001 
Hirai 2.36 (2.01-2.77) 79%, P <0.001 
Hoffmeister 2.38 (2.04-2.79) 77%, P <0.001 
Ji 2.24 (1.98-2.52) 58%, P <0.001 
Kearney (Nurses Health Study) 2.34 (1.99-2.74) 79%, P <0.001 
Kearney (Health Professionals FUS) 2.35 (2.00-2.75) 79%, P <0.001 
Lai 2.40 (2.05-2.79) 77%, P <0.001 
Lieberman 2.32 (1.98-2.73) 79%, P <0.001 
Martinez 1997 2.34 (2.00-2.74) 79%, P <0.001 
Martinez 2011 2.29 (1.96-2.67) 78%, P <0.001 
Michal 2.35 (2.01-2.76) 79%, P <0.001 
Morimoto 2.30 (1.97-2.69) 79%, P <0.001 
Noreen 2.33 (1.98-2.73) 79%, P <0.001 
Omata 2.36 (2.01-2.76) 79%, P <0.001 
Oza 2.40 (2.06-2.80) 78%, P <0.001 
Qazi 2.34 (1.99-2.75) 79%, P <0.001 
Wallace  2.37 (2.02-2.77) 79%, P <0.001 
Wang 2.36 (2.01-2.77) 79%, P <0.001 
Yoshida 2.33 (1.99-2.72) 79%, P <0.001 
OVERALL 2.34 (2.00-2.72) 78%, P <0.001 
Smoking – Hyperplastic/serrated polyps – Excluding Figueiredo and Oza studies  
(which may have had adenoma patients in comparator group) 
 2.42 (2.06-2.85) 78%, P <0.001 
Smoking – Sessile serrated adenoma/polyp only – Studies of current v. never comparisons only 
 2.86 (1.58-5.16) 71%, P <0.001 
Smoking –  Hyperplastic/serrated polyps – Studies of current v. never comparisons only 
 2.55 (2.03-3.20) 84%, P <0.001 
Smoking –  Sessile serrated adenoma/polyp only – Sub-group analysis by study design  
Including Case-control studies only 3.30 (1.77-6.15) 74%, P = 0.009 
Including Cross-sectional studies only 3.04 (0.47-19.83) 86%, P = 0.008 
Smoking –  Hyperplastic/serrated polyps – Sub-group analysis by study design*  
Including Case-control studies only 2.43 (1.95-3.03) 83%, P <0.001 
Including Cross-sectional studies only 2.11 (1.73-2.57) 57%, P = 0.02 
 
*Cohort studies were not analysed since only two cohort studies were published.
Supplementary Table 3 (b). Sensitivity and subgroup meta-analyses of alcohol and serrated polyp risk. 
 
 
Study omitted Pooled relative risk  
(95 percent CI) 
Heterogeneity estimate,  
I-squared percent, P-value 
Alcohol – Sessile serrated adenoma/polyp only – Excluding individual studies 
Burnett-Hartman 2.54 (1.43-4.51) 0%, P = 0.75 
Crockett 1.72 (0.70-4.23) 68%, P = 0.08 
Randles 1.49 (0.74-3.02) 36%, P = 0.21 
OVERALL 1.85 (1.03-3.32) 41%, P = 0.18 
Alcohol – Hyperplastic/serrated polyps – Excluding individual studies 
Burnett-Hartman  1.33 (1.17-1.52) 35%, P = 0.10 
Crockett 1.30 (1.13-1.49) 37%, P = 0.09 
Erhardt 1.30 (1.13-1.49) 37%, P = 0.09 
Fu 1.35 (1.17-1.55) 35%, P = 0.10 
Kearney (Nurses Health Study) 1.28 (1.13-1.45) 33%, P = 0.12 
Kearney (Health Professionals FUS) 1.28 (1.13-1.46) 34%, P = 0.11 
Lai 1.30 (1.13-1.48) 37%, P = 0.09 
Lieberman 1.30 (1.13-1.48) 37%, P = 0.09 
Martinez  1.28 (1.13-1.44) 31%, P = 0.14 
Michal 1.28 (1.12-1.45) 33%, P = 0.12 
Morimoto 1.30 (1.14-1.48) 38%, P = 0.08 
Omata 1.29 (1.13-1.47) 36%, P = 0.10 
Wallace  1.34 (1.20-1.50) 0%, P = 0.53 
Yoshida 1.32 (1.15-1.51) 39%, P = 0.07 
OVERALL 1.30 (1.15-1.48) 34%, P = 0.10 
Alcohol –  Sessile serrated adenoma/polyp only – Sub-group analysis by study design  
Including Case-control studies only 1.72 (0.70-4.23) 68%, P = 0.08 
Including Cross-sectional study only 2.27 (0.92-5.58) Not applicable – one study 
Alcohol –  Hyperplastic/serrated polyps – Sub-group analysis by study design*  
Including Case-control studies only 1.20 (1.04-1.37) 30%, P = 0.18 
Including Cross-sectional studies only 1.49 (1.17-1.89) 0%, P = 0.62 
 
*Cohort studies were not analysed since only two cohort studies were published.
Supplementary Table 3 (c). Sensitivity and subgroup meta-analyses of body mass index and serrated polyp risk. 
 
 
Study omitted Pooled relative risk  
(95 percent CI) 
Heterogeneity estimate,  
I-squared percent, P-value 
Body mass index – Sessile serrated adenoma/polyp only – Excluding individual studies 
Anderson 1.06 (1.02-1.11) 0%, P = 0.97 
Burnett-Hartman 1.41 (0.79-2.51) 77%, P = 0.01 
Crockett 1.37 (0.84-2.23) 77%, P = 0.01 
Randles 1.50 (0.85-2.64) 59%, P = 0.09 
OVERALL 1.30 (0.89-1.92) 66%, P = 0.03  
Body mass index – Hyperplastic/serrated polyps – Excluding individual studies 
Burnett-Hartman  1.43 (1.24-1.66) 58%, P = 0.002 
Butterly 1.42 (1.23-1.65) 58%, P = 0.002 
Crockett 1.43 (1.24-1.66) 58%, P = 0.002 
Erhardt 1.43 (1.24-1.64) 58%, P = 0.002 
Fu 1.43 (1.23-1.67) 58%, P = 0.002 
Hirai 1.44 (1.23-1.68) 58%, P = 0.002 
Lai 1.41 (1.23-1.63) 58%, P = 0.003 
Leitzmann 1.34 (1.22-1.46) 10%, P = 0.34 
Martinez  1.39 (1.23-1.57) 48%, P = 0.002 
Morimoto (males) 1.41 (1.23-1.62) 58%, P = 0.003 
Morimoto (females) 1.44 (1.25-1.65) 58%, P = 0.003 
Noreen 1.46 (1.28-1.66) 53%, P = 0.008 
Omata 1.43 (1.24-1.64) 58%, P = 0.002 
Oza 1.44 (1.26-1.65) 56%, P = 0.004 
Wallace  1.45 (1.25-1.69) 56%, P = 0.005 
Wang 1.44 (1.24-1.67) 58%, P = 0.002 
OVERALL 1.42 (1.24-1.63) 55%, P = 0.004 
Body mass index – Hyperplastic/serrated polyps – Excluding Oza and Wang studies  
(which may have had adenoma patients in comparator group) 
 1.46 (1.26-1.69) 59%, P = 0.003 
Body mass index –  Sessile serrated adenoma/polyp only – Sub-group analysis by study design  
Including Case-control studies only 1.06 (1.02-1.11) 0%, P = 0.83 
Including Cross-sectional studies only 1.76 (0.78-3.99) 64%, P = 0.10 
Body mass index –  Hyperplastic/serrated polyps – Sub-group analysis by study design  
Including Case-control studies only 1.29 (1.16-1.43) 0%, P = 0.63 





Supplementary Table 3 (d). Sensitivity and subgroup meta-analyses of physical activity and serrated polyp risk. 
 
 
Study omitted Pooled relative risk  
(95 percent CI) 
Heterogeneity estimate,  
I-squared percent, P-value 
Physical activity – Hyperplastic/serrated polyps – Excluding individual studies* 
Burnett-Hartman  0.91 (0.78-1.05) 5%, P = 0.39 
Crockett 0.89 (0.76-1.03) 4%, P = 0.40 
Fu 1.50 (0.85-2.64) 7%, P = 0.38 
Lieberman 0.92 (0.79-1.07) 1%, P = 0.42 
Martinez  0.91 (0.79-1.05) 0%, P = 0.55 
Morimoto (males) 0.91 (0.79-1.04) 0%, P = 0.43 
Morimoto (females) 0.87 (0.76-1.00) 0%, P = 0.84 
Wallace  0.87 (0.75-1.01) 0%, P = 0.46 
Yoshida 0.91 (0.78-1.05) 4%, P = 0.40 
OVERALL 0.90 (0.78-1.03) 0%, P = 0.48  
Physical activity –  Hyperplastic/serrated polyps – Sub-group analysis by study design  
Including Case-control studies only 0.90 (0.77-1.05) 0%, P = 0.45 
Including Cross-sectional studies only 0.81 (0.48-1.38) 42%, P = 0.19 
 
*Not conducted for sessile serrated adenoma studies since only two studies published. 
**May have included individuals with adenomas in the comparator group.  
Supplementary Table 3 (e). Sensitivity and subgroup meta-analyses of medication use and serrated polyp risk. 
 
 
Study omitted Pooled relative risk  
(95 percent CI) 
Heterogeneity estimate,  
I-squared percent, P-value 
Medications, NSAIDs – Hyperplastic/serrated polyps – Excluding individual studies* 
Burnett-Hartman 0.74 (0.60-0.92) 60%, P = 0.02 
Crockett 0.74 (0.61-0.88) 50%, P = 0.06 
Drew 0.79 (0.67-0.93) 52%, P = 0.05 
Fu  0.74 (0.59-0.93) 61%, P = 0.02 
Johnson 0.79 (0.64-0.97) 56%, P = 0.03 
Lieberman 0.77 (0.62-0.95) 62%, P = 0.02 
Martinez  0.81 (0.70-0.94) 43%, P = 0.10 
Morimoto 0.78 (0.65-0.95) 61%, P = 0.02 
OVERALL 0.74 (0.60-0.92) 60%, P = 0.02  
Medications, NSAIDs –  Hyperplastic/serrated polyps – Sub-group analysis by study design  
Including Case-control studies only 0.78 (0.70-0.87) 0%, P = 0.46 
Including Cross-sectional studies only 0.42 (0.12-1.44) 83%, P = 0.003 
Medications, Aspirin – Hyperplastic/serrated polyps – Excluding individual studies 
Drew** 0.77 (0.60-0.98) 35%, P = 0.19 
Johnson 0.85 (0.68-1.07) 30%, P = 0.22 
Morimoto 0.79 (0.63-0.98) 41%, P = 0.15 
Murff  0.78 (0.61-1.00) 44%, P = 0.13 
Noreen 0.85 (0.73-0.99) 0%, P = 0.60 
Oza*** 0.81 (0.65-1.01) 46%, P = 0.12 
OVERALL 0.81 (0.67-0.99) 33%, P = 0.19  
Medications, Hormone Replacement Therapy – Hyperplastic/serrated polyps*  
– Excluding individual studies* 
Burnett-Hartman 1.02 (0.72-1.44) 36%, P = 0.21 
Crockett 0.92 (0.70-1.23) 9%, P = 0.33 
Morimoto 1.09 (0.84-1.40) 0%, P = 0.60 
Noreen 0.94 (0.70-1.27) 25%, P = 0.26 
OVERALL 0.99 (0.78-1.26) 0%, P = 0.34  
Medications, Aspirin –  Hyperplastic/serrated polyps– Sub-group analysis by study design  
Including Case-control studies only 0.92 (0.70-1.22) 9%, P = 0.33 
Including Cross-sectional study only 1.22 (0.79-1.89) Not applicable – one study 
 
*Not conducted for sessile serrated adenoma studies since only two studies published. 
** Denotes cross-sectional study design. All other studies were case-control studies. 









Study omitted Pooled relative risk  
(95 percent CI) 
Heterogeneity estimate,  
I-squared percent, P-value 
Vitamin D – Hyperplastic/serrated polyps 
Kearney** 1.13 (0.75-1.69) 52%, P = 0.15 
Lieberman 1.18 (0.75-1.86) 34%, P = 0.22 
Morimoto 1.00 (0.99-1.01) 0%, P = 0.96 
OVERALL 1.00 (0.94-1.07) 4%, P = 0.36  
Calcium – Hyperplastic/serrated polyps 
Fu 0.69 (0.38-1.25) 70%, P = 0.04 
Lieberman 0.66 (0.49-0.90) 13%, P = 0.32 
Martinez* 0.83 (0.62-1.12) 73%, P =0.03 
Morimoto 0.80 (0.56-1.14) 79%, P = 0.01 
OVERALL 0.76 (0.55-1.06) 74%, P = 0.009  
Total folate – Hyperplastic/serrated polyps 
Fu 1.02 (0.72-1.44) 51%, P = 0.15 
Kearney (Nurses’ Health Study)** 0.92 (0.70-1.23) 0%, P = 0.91 
Kearney (Health Professionals FUS)** 1.09 (0.84-1.40) 66%, P = 0.09 
OVERALL 0.99 (0.78-1.26) 0%, P = 0.34  
Dietary fiber – Hyperplastic/serrated polyps 
Crockett* 0.91 (0.79-1.04) 44%, P = 0.11 
Fu 0.88 (0.76-1.03) 50%, P = 0.07 
Kearney (Nurses’ Health Study)** 0.89 (0.77-1.02) 53%, P = 0.06 
Lieberman 0.84 (0.74-0.95) 0%, P = 0.48 
Martinez* 0.93 (0.85-1.03) 27%, P = 0.23 
Platz** 0.88 (0.76-1.02) 54%, P = 0.05 
Wallace 0.85 (0.70-1.03) 51%, P = 0.07 
OVERALL 0.88 (0.77-1.01) 48%, P = 0.07 
Total fat – Hyperplastic/serrated polyps 
Crockett* 1.22 (1.07-1.39) 0%, P = 0.74 
Fu 1.25 (1.09-1.43) 0%, P = 0.60 
Kearney (Nurses’ Health Study)** 1.26 (1.11-1.43) 0%, P = 0.70 
Kearney (Health Professionals FUS)**  1.28 (1.12-1.45) 0%, P = 0.84 
Martinez* 1.25 (1.11-1.41) 0%, P = 0.65 
Morimoto 1.25 (1.11-1.42) 0%, P = 0.62 
Wallace 1.19 (1.00-1.41) 0%, P = 0.69 
OVERALL 1.25 (1.10-1.41) 0%, P = 0.72 
Red meat – Hyperplastic/serrated polyps 
Burnett-Hartman 1.21 (1.04-1.40) 0%, P = 0.57 
Crockett* 1.23 (1.06-1.43) 0%, P = 0.52 
Fu 1.18 (1.01-1.39) 0%, P = 0.76 
Wallace 1.31 (1.08-1.58) 0%, P = 0.76 
OVERALL 1.23 (1.07-1.41) 0%, P = 0.72 
 
*Denotes cross-sectional study design. All other studies were case-control studies or cohort studies (Kearney/Platz). 






















Serrated polyp definition   
 
 
Pathology review details 
 
 
Quality of colonoscopy  





SESSILE SERRATED ADENOMA/POLYPS     
Anderson et al (2011)  
USA 
Jan 2007-  
Sept 2010 
SSA/P excluding TSA and 
HP (all, and subgroup 
analysis by size - ≥1cm 
and ≥6mm) 
All pathologists at University of Connecticut 
Health Center 
Not reported. Cross-sectional 
study 




SSA/P including SSA/P 
with dysplasia.  
TSA and HP excluded. 
Two experienced gastrointestinal pathologists 
conducted independent review including 
consensus agreement where appropriate.  
All colonoscopies conducted by one of 
four gastroenterologists. Poor bowel 
preparation colonoscopies were excluded.  
Hospital-based 
case control 
Burnett-Hartman et al (2013)   
USA  
1998-2007 SSA/P.   
TSA and HP excluded. 
Two study pathologists re-reviewed polyps to 
identify SSA/P (displaying exaggerated crypt 
serration, crypt dilatation, crypt, branching, 
horizontal crypt extensions at base or other 
distortions).  




Crockett et al (2014)/ 
Crockett et al (2015) 
USA  
1998-2010 Proximal and large SSA/P Proximal and large SPs diagnosed at the 
University of North Carolina were re-reviewed by 
an expert pathologist.  
Not reported (abstract).  Pooled data 
from cross-
sectional studies 
Davenport et al (2014)  
USA  
2003-2010 SSA/P All polyps within the Tennessee Colorectal Polyp 
Study were re-reviewed by a study pathologist.  
Colonoscopy that reached the caecum. Hospital-based 
case control 
Randles et al (2015)  
USA  
July 2009 –  
Oct 2008 
SSA/P  
(all, subgroup analysis by 
size and location) 
All SSA/Ps re-reviewed by one of two expert 
gastrointestinal pathologists according to 2012 
guidelines. 
Colonoscopies conducted at University of 




HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED OR COMBINED    
Adams et al (2011) 
USA 
1999-2003 HP Unspecified, routine pathology review.  All subjects underwent colonoscopy at the 




Burnett-Hartman et al (2011)  
USA  
Dec 2004 –  
Sept 2007 
HP Unspecified, routine pathology review.  Colonoscopies not reaching the caecum or 




Burnett-Hartman et al (2013)  
USA  
1998-2007 HP  
SSA/P and TSA excluded.  
A combined HP and 
SSA/P subgroup analysis 
was conducted by 
proximal/distal site.   
Two study pathologists re-reviewed polyps to 
identify HP  
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HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED OR COMBINED    
Butterly et al (2014) 
USA 
6 April 2009 -
22 March 
2011 
SSA/P and HP combined All pathology reports in the New Hampshire 
Colonoscopy Registry. 
Poor, fair or unknown bowel preparation 
colonoscopies were excluded. 
Colonoscopies excluded where 
endoscopist unknown or by two 
endoscopists who didn’t provide 
withdrawal time. Normal withdrawal 




Crockett et al (2014) 
USA  
1998-2010 Proximal and large SP 
(including SSA/P) 
Proximal and large SPs diagnosed at the 
University of North Carolina were re-reviewed by 
an expert pathologist.  
Not reported (abstract).  Pooled data 
from cross-
sectional studies 
Dai et al (2007)/  
Fu et al (2011 & 2012)/ 
Murff et al (2011 & 2012) 
USA 
1 Feb 2003 -
31 May 2008 
HP Unspecified, routine pathology review.  Screening or diagnostic colonoscopies  
that reached the caecum at Vanderbilt 
Gastroenterology Clinic or Veteran’s 
Affairs Tennessee Valley Health System.   
Hospital-based 
case-control 
Davenport et al (2014)   
USA  
1 Feb 2003 -
31 May 2008 
HP only (excluding SSA). All polyps within the Tennessee Colorectal Polyp 
Study were re-reviewed by a study pathologist.  
Colonoscopy that reached the caecum. Hospital-based 
case-control 
Drew et al (2016) 
USA 
Jan 2011 - 
June 2014 
SSA/HP/TSA combined Unspecified, routine pathology review.  Colonoscopy. Split-dose bowel prep used.  Cross-sectional 
study 
Erhardt et al (2002)  
Germany 
March 1995 – 
Oct 1997 
HP Histological assessment was performed by one of 
two staff pathologists at the Robert-Bosch 
Hospital. 
Colonoscopy was performed jointly by a 
staff gastroenterologist and an 
experienced endoscopy nurse.  
Incomplete colonoscopies (not reaching 
caecum) or unsatisafactory colon 
preparation were excluded.  
Hospital-based 
case-control 






Subgroup analysis of 
large SP (≥1cm) 
All slides reviewed by a single study pathologist. Colonoscopy or surgery specimens 
collected within the trial protocols.  
Nested case-
control study in 
RCT 
Hassan et al (2010) / 




HP Histological review within trial. Pathologist detail 
not reported. 
All individuals underwent standard bowel 
preparation and optical colonoscopy by 
one of 17 colonoscopists in a low-dose CT 
colonography screening trial (that also 
included optical colonoscopy). 
Cross-sectional 
study in RCT 
Hirai et al (2013)  
China  
2007-2013 SSA/HP combined Not reported (abstract). Not reported (abstract). Cross-sectional 
study 
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HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED OR COMBINED    




HP All pathology reports from population-based 
KolosSal study in Saarland, South-West Germany, 
were reviewed by two independent investigators. 
Screening colonoscopies from 33 
gastroenterology practices in Saarland. 
Colonoscopies unable to reach caecum or 




Ji et al (2006) /  




Distal HP Histological review within trial. Pathologist detail 
not reported. 
Screening flexible sigmoidoscopies within 
the PLCO Cancer Screening trial, and 
multi-centre study in the USA. 
Nested case-
control study in 
RCT 
Kearney et al (1995) /  






Distal HP  Review of histopathology reports following self-
report of a colorectal polyp diagnosis.  
All subjects underwent colonoscopy or 
sigmoidoscopy during cohort study follow-




Lai et al (2013)  
Taiwan 
2001-2004 Distal HP  
(assumed distal due to 
flexible sigmoidoscopy) 
All medical records from one medical center at 
Taichung city were reviewed. Pathologist detail 
not reported.  
All subjects underwent 60cm flexible 
sigmoidoscopy. Quality not reported. 
Cross-sectional 
study 
Lieberman et al (2003)  
USA 
Feb 1994 –  
Jan 1997 
HP All retrieved polyps were sent to local pathology 
laboratories for histologic evaluation. Slides were 
sent to a designated pathology expert at the 
Veterans Affairs Medical Center in Hines, Illinois, 
for an independent, blinded review. The results 
of the third review were used to classify any 
disagreements. 
All subjects underwent complete 
colonoscopy at one of 13 Veterans Affairs 
medical centers in the USA.  If the 
colonoscopic examination was incomplete 
because of problems with bowel 
preparation or failure to reach the cecum, 




Lietzmann et al (2009) 
 
1 July 1999 -
31 Dec 2002 
HP  
(all, subgroup analysis 
conducted for small, 
large, multiple, proximal, 
distal, rectal HP) 
All histological specimens were reviewed by one 
expert gastrointestinal pathologist. 
>99% colonoscopies performed by 
gastroenterologists or colorectal 
surgeons.  Quality not reported. 
Cross-sectional 
study 
Liu et al (2010) Jan 2006 - 
May 2008 
HP All specimens reviewed by pathologists at China 
Medical University Hospital. 








HP Medical record review from medical centres of 
participating gastroenterologists. 
Endoscopies performed by one of eight 
gastroenterologists. Quality not reported. 
Cross-sectional 
study 
Martinez et al (2011)  
USA 
Jan 1998 –  
Feb 2001 
HP Not reported. All subjects underwent 60cm flexible 
sigmoidoscopy performed by the same 
endoscopist. Quality not reported. 
Cross-sectional 
study 
Supplementary Table 4 continued. Details of pathology review, serrated polyp definition and colonoscopy quality in included studies.  
 
HPFUS: Health Professionals Follow Up Study; HP: Hyperplastic polyp; NHS: Nurses’ Health Study RCT: Randomised controlled trial; SSA/P: Sessile serrated adenoma/polyp; 
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HYPERPLASTIC POLYPS/SERRATED POLYPS UNSPECIFIED OR COMBINED    




HP Not reported (abstract). Patients undergoing screening colonoscopy at 
one institution.  Quality not reported (abstract). 
Hospital-based 
case-control 
Morimoto et al (2002) / 




HP Review by study pathologist. Colonoscopy that reached the caecum, 
performed at a large multicenter private 
gastroenterology practice.  Quality of bowel 
preparation not reported. 
Hospital-based 
case-control 
Noreen et al (2014)   
Poland 
2000-2004 SSA and HP combined Local pathology review at participating 
centres. 
Colonoscopies within 40 centres participating in 





Omata et al (2009)  
Japan 
Not reported HP Not reported. Patients undergoing colonoscopy at Tokai 
University Oiso Hospital. Quality not reported. 
Hospital-based 
case-control  
Oza et al (2014) 
Not reported 
Three month 
period in 2012 
Proximal SP  
(HP/SSA/TSA combined) 
Not reported (abstract). Adequate bowel preparation (good, very good 
or excellent) for outpatients undergoing 
screening colonoscopy at a single academic 
tertiary care referral center.  
Hospital-based 
case-control 




HP (microvesicular or 
goblet cell) 
All specimens reviewed by a study 
pathologist.  
Not reported (abstract). Hospital-based 
case-control 






HP All specimens reviewed by a study 
pathologist. 
All subjects underwent two follow-up 
colonoscopies as part of their routine clinical 
care, usually by the same physician who had 










HP/SSA/TSA and mixed 
serrated polyps 
combined 
All specimens reviewed by study 
pathologists, with noted change from HP to 
serrated adenoma towards latter study 
years. 
Colonoscopy that reached the caecum, with 
endoscopist attesting to removal of all 




within RCTs***  
Wang et al (2014)  
Taiwan 
Jan 2009 –  
Dec 2011 
HP only  
(excluding SSA and TSA). 
Pathologist categorised polyps into HP, 
SSA/P, TSA or adenomatous polyps. 
Colonoscopies performed by one of three 
experienced endoscopists. Quality of bowel 
preparation not reported. 
Cross-sectional 
study 




HP Not reported. Colonoscopies reaching the caecum, performed 
by one of three experienced endoscopists 
following careful bowel preparation of patients. 
Hospital-based 
case-control 
